2 results
Approved WMOWill not start
To determine whether aleglitazar reduces cardiovasculair mortality and morbidity (defined as non-fatal myocardial infarction (MI) and non-fatal stroke) in patients with a recent ACS event and type 2 diabetes.
Approved WMOCompleted
The primary objective is to evaluate the feasibility and adherence of 6 weeks of rehabilitation with the SEA in participants who underwent TL. The secondary objective is to examine if the SEA is an effective tool to improve swallowing function and…